Pharmacy costs continue to rise in 2026, driven by specialty medications, GLP‑1 utilization, and new gene‑therapy treatments. Many employers are discovering that their medical carriers’ pharmacy programs offer limited transparency and few levers for cost control. As a result, pharmacy carve‑outs—where employers contract directly with a PBM—are gaining traction. [September 2026, 474 word article]